Carl O. Landgren

Carl O. Landgren

Hematology Oncology | Hematology | Oncology

5555 Ponce De Leon Boulevard
Coral Gables, FL 33146

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Navigating the Therapeutic Landscape of Multiple Myeloma: Immunotherapy, Microenvironment, and Resistance.

Navigating the Therapeutic Landscape of Multiple Myeloma: Immunotherapy, Microenvironment, and Resistance.

Journal: Biomedicines

Published: May 27, 2026

Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH).

Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH).

Journal: Blood

Published: May 15, 2025

Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations.

Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations.

Journal: Blood advances

Published: September 06, 2022

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.

Journal: Blood cancer discovery

Published: June 02, 2022

Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets.

Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 07, 2022

Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls.

Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls.

Journal: Haematologica

Published: March 16, 2021

CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging.

CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging.

Journal: Radiology

Published: April 08, 2020

Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.

Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.

Journal: Blood reviews

Published: April 07, 2020

Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders.

Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders.

Journal: Best practice & research. Clinical haematology

Published: January 11, 2020

Second malignancies in multiple myeloma; emerging patterns and future directions.

Second malignancies in multiple myeloma; emerging patterns and future directions.

Journal: Best practice & research. Clinical haematology

Published: December 30, 2019

Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis.

Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis.

Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

Published: June 17, 2019

Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

Published: September 11, 2018

Showing 1-12 of 18

Last Updated: 09/26/2026